New York’s doctors experimented on a cancer drug dostarlimab that came out to be a successful trial with a success rate of 100 percent.
The New York’s Memorial Sloan Kettering Cancer Center conducted an experiment according to which cancer drug has shown a success rate of 100% in a small study trial on patients with rectal cancer. The 18 participants were reportedly administered an experimental drug called “dostarlimab” for six months and following the trial, every single one of their tumors was found to have disappeared.
According to the FDA website, the United States Food and Drug Authority (FDA) had only approved the drug for human trial “for at least 300 patients across all tumor types” in early August 2021.
Read more: Research shows ants can be trained to detect cancer in humans
Dr. Hanna Sanoff, who is one of the people who have written about the results, in an interview with NPR explained the mechanism by which the drug works. “This drug is one of a class of drugs called immune checkpoint inhibitors. These are immunotherapy medicines that work not by directly attacking the cancer itself, but actually getting a person’s immune system to essentially do the work,”
She added, “These are drugs that have been around in melanoma and other cancers for quite a while, but really have not been part of the routine care of colorectal cancers until fairly recently,”
She also added that no severe side-effects for the participants of the study were found, which means the experiment was conducted successfully.
Moreover, another study by Dr. Anthony Markham showed only 10 percent of the patients participating in the experimental trial experienced adverse effects, such as, anemia, nausea, and fatigue. The group of researchers currently conducting trials of dosterlimab express a sense of optimism around the drug’s potential.
